ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 35 for:    smoking [CONDITION] AND child [AGE-GROUP] | Recruiting, Not yet recruiting, Available Studies

Evaluating New Nicotine Standards for Cigarettes - Project 3 (CENIC2-P3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03194256
Recruitment Status : Not yet recruiting
First Posted : June 21, 2017
Last Update Posted : June 21, 2017
Sponsor:
Collaborators:
University of Pittsburgh
University of Minnesota - Clinical and Translational Science Institute
Information provided by (Responsible Party):
Suzanne M. Colby, Brown University

Brief Summary:
This study is designed to examine how the nicotine content of cigarettes and the nicotine concentration and flavors in e-liquids influence responses to and use of these products in adolescent smokers. Participants will complete a total of six sessions (an in-person screening/baseline session and five lab sessions.

Condition or disease Intervention/treatment Phase
Smoking, Cigarette Electronic Cigarettes Behavioral: Spectrum Research Cigarettes Not Applicable

Detailed Description:

Adolescence is a critical developmental period for tobacco initiation and progression to regular use and dependence. The Food and Drug Administration (FDA) has the authority to establish standards for tobacco products for the protection of public health, including the authority to mandate a reduction in the nicotine content of all cigarettes to minimally addictive levels. Numerous studies have found that adult smokers who are switched to very low nicotine content (VLNC) cigarettes experience reductions in smoking rates, nicotine intake, nicotine dependence and abstinence-induced craving relative to those who use normal nicotine content (NNC) cigarettes. However, studies of VLNC cigarettes in adolescent smokers are limited and more information is needed to inform potential product standards. Furthermore, use of electronic nicotine delivery systems (ENDS), e-cigarettes or vaping devices, has increased dramatically in adolescents. Therefore, effects of VLNC cigarettes on smoking in youth should be examined in the context of vaping device availability. This study is designed to examine how the nicotine content of cigarettes and the nicotine concentration and flavors in e-liquids influence responses to these products in adolescents.

Participants will complete an in-person baseline session in which eligibility criteria are confirmed and background questionnaires are completed. Next, participants will complete five in-person lab sessions in which NNC or VLNC cigarettes are available (based on random assignment). During the first lab session, participants will test the assigned research cigarettes when no alternative product is available. During each of the four remaining lab sessions, smokers' responses to the assigned research cigarettes will be compared to their responses to a vaping device with the following characteristics: 1) no nicotine, tobacco flavor; 2) no nicotine, non-tobacco flavor; 3) moderate nicotine concentration, tobacco flavor; or 4) moderate nicotine concentration, non-tobacco flavor. In each session, after sampling and rating the subjective effects of the products available during that session, participants will make a series of 10 choices. Choices will be for either 2 puffs of the research cigarette, 2 puffs of the vaping device, or abstinence from puffing.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Mixed between subjects and within-subjects design. Random assignment to the between subjects factor (nicotine content in cigarettes), within-subjects manipulation of nicotine concentration and flavors in e-liquid in the electronic cigarettes
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description: Participants will be blind to the nicotine content of their assigned study cigarette and the nicotine dose of the e-liquid in the study vaping device. Investigators, research staff, and biostatisticians will also be blind to the conditions. E-liquid flavors will not be blinded.
Primary Purpose: Other
Official Title: Effects of Very Low Nicotine Content Cigarettes and E-cigarette Characteristics on Smoking in Adolescents
Estimated Study Start Date : September 1, 2017
Estimated Primary Completion Date : February 28, 2022
Estimated Study Completion Date : February 28, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: E-Cigarettes

Arm Intervention/treatment
Active Comparator: Normal Nicotine Content Cigarettes
Spectrum Research Cigarettes: 15.8 mg nicotine/g tobacco, 9 mg of tar
Behavioral: Spectrum Research Cigarettes
Participants will be assigned to either normal nicotine content cigarettes or very low nicotine content cigarettes.

Experimental: Very Low Nicotine Content Cigarettes
Spectrum Research Cigarettes: 0.4 mg nicotine/g tobacco, 9 mg of tar
Behavioral: Spectrum Research Cigarettes
Participants will be assigned to either normal nicotine content cigarettes or very low nicotine content cigarettes.




Primary Outcome Measures :
  1. Change in the number of cigarette puffs taken [ Time Frame: 60-minute preference task session ]
    The number of cigarette puffs selected during a 60 minute choice procedure, as a function of availability (yes/no) and characteristics (nicotine concentration; flavors) of a vaping device.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years to 19 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Ages 15-19
  2. Adolescents who report current daily cigarette smoking
  3. Must have used an electronic nicotine device on a minimum of two lifetime occasions.
  4. Breath Carbon Monoxide (CO) levels > 5 ppm (if < 5 ppm, then cotinine assay via NicAlert Strip = > 3)
  5. Speak, comprehend, and read English well enough to complete study procedures

Exclusion Criteria:

  1. Unwilling to use research cigarettes or ENDS as part of the study
  2. Intention to quit smoking in the next 30 days
  3. Using ENDS > 25 days in the past 30 days
  4. Contemplation Ladder Score > 7 indicating a definite plan to quit smoking in the next 30 days.
  5. Using tobacco products (other than ENDS or roll-your-own tobacco) > 10 days in the past 30 days.
  6. Any medical or psychiatric condition in which participation is likely to post a significant threat to health or for which the condition could interfere with the ability of the participant to fully participants (as determined by the LMP)
  7. Self-reported illicit use of any drug except marijuana > 10 days in the past 30 days
  8. Binge drinking alcohol (>10 days in the past 30 days, >4/5 drinks in a 2-hour period (female/male))
  9. Pregnant or breastfeeding
  10. CO reading > 80 ppm
  11. Systolic BP outside the range of 90-159, diastolic BP outside the range of 50-99, or heart rate outside the range of 45-104. Participants failing for any of these criteria will be allowed to re-screen once per criterion.
  12. Indicating Yes on Questions 4-6 on the MINI with a suicide attempt in the past 5 years (if within the past 6-10 years, LMP approval required).
  13. Having participated in another research study during the past year in which they were switched to reduced nicotine cigarettes for longer than one week.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03194256


Contacts
Contact: Suzanne Colby, PhD (401) 863-6655 suzanne_colby@brown.edu

Locations
United States, Rhode Island
Brown University School of Public Health Not yet recruiting
Providence, Rhode Island, United States, 02912
Contact: Rachel Denlinger-Apte, MPH    412-525-9798    rachel_denlinger@brown.edu   
Principal Investigator: Suzanne Colby, PhD         
Principal Investigator: Jennifer Tidey, PhD         
Sub-Investigator: Rachel Cassidy, PhD         
Sub-Investigator: Patricia Cioe, PhD         
Sponsors and Collaborators
Brown University
University of Pittsburgh
University of Minnesota - Clinical and Translational Science Institute
Investigators
Principal Investigator: Suzanne Colby, PhD Brown University

Responsible Party: Suzanne M. Colby, Multi-PI, Brown University
ClinicalTrials.gov Identifier: NCT03194256     History of Changes
Other Study ID Numbers: 1705001771
First Posted: June 21, 2017    Key Record Dates
Last Update Posted: June 21, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Suzanne M. Colby, Brown University:
Smoking
Cigarettes
E-Cigarettes

Additional relevant MeSH terms:
Nicotine
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action